Fig. 2From: Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)Progressive increase in risk and decrease in benefit with actively raised hemoglobin levels from 8 to 14 g/dL (from Fishbane and Spinowitz, Am J Kidney Dis 2018; 71: 423–435)Back to article page